vs
英美资源集团（AMSC）与MESA LABORATORIES INC（MLAB）财务数据对比。点击上方公司名可切换其他公司
英美资源集团的季度营收约是MESA LABORATORIES INC的1.1倍（$74.5M vs $65.1M），英美资源集团净利率更高（158.1% vs 5.6%，领先152.5%），英美资源集团同比增速更快（21.4% vs 3.6%），MESA LABORATORIES INC自由现金流更多（$18.0M vs $2.4M），过去两年英美资源集团的营收复合增速更高（33.2% vs 5.1%）
英美资源集团是一家总部位于英国伦敦的跨国矿业企业，是全球最大的铂金生产商，产量约占全球总产出的40%，同时也是钻石、铜、镍、铁矿石、多卤石、炼焦煤的主要供应商，业务布局覆盖非洲、亚洲、大洋洲、欧洲、南北美洲多个地区。
梅萨实验室有限公司开发、生产和销售专业质控、校准及监测仪器与配套服务，核心业务覆盖医疗健康、制药、食品饮料、工业卫生及环境检测领域，为全球客户满足合规及运营安全需求提供支持。
AMSC vs MLAB — 直观对比
营收规模更大
AMSC
是对方的1.1倍
$65.1M
营收增速更快
AMSC
高出17.7%
3.6%
净利率更高
AMSC
高出152.5%
5.6%
自由现金流更多
MLAB
多$15.7M
$2.4M
两年增速更快
AMSC
近两年复合增速
5.1%
损益表 — Q3 FY2026 vs Q3 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $74.5M | $65.1M |
| 净利润 | $117.8M | $3.6M |
| 毛利率 | 30.7% | 64.2% |
| 营业利润率 | 4.5% | 12.2% |
| 净利率 | 158.1% | 5.6% |
| 营收同比 | 21.4% | 3.6% |
| 净利润同比 | 4679.1% | 316.6% |
| 每股收益（稀释后） | $2.62 | $0.65 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AMSCMLAB
| Q4 25 | $74.5M | $65.1M | ||
| Q3 25 | $65.9M | $60.7M | ||
| Q2 25 | $72.4M | $59.5M | ||
| Q1 25 | $66.7M | $62.1M | ||
| Q4 24 | $61.4M | $62.8M | ||
| Q3 24 | $54.5M | $57.8M | ||
| Q2 24 | $40.3M | $58.2M | ||
| Q1 24 | $42.0M | $58.9M |
净利润AMSCMLAB
| Q4 25 | $117.8M | $3.6M | ||
| Q3 25 | $4.8M | $2.5M | ||
| Q2 25 | $6.7M | $4.7M | ||
| Q1 25 | $1.2M | $-7.1M | ||
| Q4 24 | $2.5M | $-1.7M | ||
| Q3 24 | $4.9M | $3.4M | ||
| Q2 24 | $-2.5M | $3.4M | ||
| Q1 24 | $-1.6M | $-254.6M |
毛利率AMSCMLAB
| Q4 25 | 30.7% | 64.2% | ||
| Q3 25 | 31.0% | 61.5% | ||
| Q2 25 | 33.8% | 62.0% | ||
| Q1 25 | 26.5% | 61.8% | ||
| Q4 24 | 26.6% | 63.3% | ||
| Q3 24 | 28.7% | 61.3% | ||
| Q2 24 | 30.3% | 64.0% | ||
| Q1 24 | 24.8% | 62.1% |
营业利润率AMSCMLAB
| Q4 25 | 4.5% | 12.2% | ||
| Q3 25 | 4.5% | 7.8% | ||
| Q2 25 | 7.8% | 5.1% | ||
| Q1 25 | 2.5% | 2.4% | ||
| Q4 24 | 2.1% | 9.2% | ||
| Q3 24 | -1.4% | 6.1% | ||
| Q2 24 | -8.2% | 9.6% | ||
| Q1 24 | -5.3% | -460.6% |
净利率AMSCMLAB
| Q4 25 | 158.1% | 5.6% | ||
| Q3 25 | 7.2% | 4.1% | ||
| Q2 25 | 9.3% | 8.0% | ||
| Q1 25 | 1.8% | -11.4% | ||
| Q4 24 | 4.0% | -2.7% | ||
| Q3 24 | 9.0% | 5.9% | ||
| Q2 24 | -6.3% | 5.8% | ||
| Q1 24 | -3.8% | -432.2% |
每股收益（稀释后）AMSCMLAB
| Q4 25 | $2.62 | $0.65 | ||
| Q3 25 | $0.11 | $0.45 | ||
| Q2 25 | $0.17 | $0.85 | ||
| Q1 25 | $0.04 | $-1.30 | ||
| Q4 24 | $0.06 | $-0.31 | ||
| Q3 24 | $0.13 | $0.63 | ||
| Q2 24 | $-0.07 | $0.62 | ||
| Q1 24 | $-0.03 | $-47.26 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $141.1M | $29.0M |
| 总债务越低越好 | — | $68.4M |
| 股东权益账面价值 | $536.8M | $186.7M |
| 总资产 | $719.5M | $434.8M |
| 负债/权益比越低杠杆越低 | — | 0.37× |
8季度趋势，按日历期对齐
现金及短期投资AMSCMLAB
| Q4 25 | $141.1M | $29.0M | ||
| Q3 25 | $212.9M | $20.4M | ||
| Q2 25 | $207.9M | $21.3M | ||
| Q1 25 | $79.5M | $27.3M | ||
| Q4 24 | $75.2M | $27.3M | ||
| Q3 24 | $72.1M | $24.3M | ||
| Q2 24 | $93.5M | $28.5M | ||
| Q1 24 | $90.5M | $28.2M |
总债务AMSCMLAB
| Q4 25 | — | $68.4M | ||
| Q3 25 | — | $69.4M | ||
| Q2 25 | — | $70.3M | ||
| Q1 25 | — | $71.3M | ||
| Q4 24 | — | $72.2M | ||
| Q3 24 | — | $73.1M | ||
| Q2 24 | — | $74.1M | ||
| Q1 24 | — | — |
股东权益AMSCMLAB
| Q4 25 | $536.8M | $186.7M | ||
| Q3 25 | $342.2M | $178.5M | ||
| Q2 25 | $333.1M | $172.5M | ||
| Q1 25 | $197.1M | $159.8M | ||
| Q4 24 | $192.7M | $155.2M | ||
| Q3 24 | $187.0M | $161.5M | ||
| Q2 24 | $143.3M | $150.7M | ||
| Q1 24 | $144.6M | $145.4M |
总资产AMSCMLAB
| Q4 25 | $719.5M | $434.8M | ||
| Q3 25 | $445.6M | $430.4M | ||
| Q2 25 | $452.8M | $435.7M | ||
| Q1 25 | $310.5M | $433.3M | ||
| Q4 24 | $310.3M | $433.3M | ||
| Q3 24 | $298.4M | $454.1M | ||
| Q2 24 | $240.1M | $440.4M | ||
| Q1 24 | $232.8M | $446.8M |
负债/权益比AMSCMLAB
| Q4 25 | — | 0.37× | ||
| Q3 25 | — | 0.39× | ||
| Q2 25 | — | 0.41× | ||
| Q1 25 | — | 0.45× | ||
| Q4 24 | — | 0.47× | ||
| Q3 24 | — | 0.45× | ||
| Q2 24 | — | 0.49× | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $3.2M | $18.8M |
| 自由现金流经营现金流 - 资本支出 | $2.4M | $18.0M |
| 自由现金流率自由现金流/营收 | 3.2% | 27.7% |
| 资本支出强度资本支出/营收 | 1.2% | 1.1% |
| 现金转化率经营现金流/净利润 | 0.03× | 5.17× |
| 过去12个月自由现金流最近4个季度 | $16.0M | $37.9M |
8季度趋势，按日历期对齐
经营现金流AMSCMLAB
| Q4 25 | $3.2M | $18.8M | ||
| Q3 25 | $6.5M | $8.2M | ||
| Q2 25 | $4.1M | $1.9M | ||
| Q1 25 | $6.3M | $12.7M | ||
| Q4 24 | $5.9M | $18.1M | ||
| Q3 24 | $12.7M | $5.3M | ||
| Q2 24 | $3.4M | $10.7M | ||
| Q1 24 | $2.2M | $12.9M |
自由现金流AMSCMLAB
| Q4 25 | $2.4M | $18.0M | ||
| Q3 25 | $5.1M | $7.1M | ||
| Q2 25 | $3.3M | $884.0K | ||
| Q1 25 | $5.3M | $11.9M | ||
| Q4 24 | $5.3M | $17.3M | ||
| Q3 24 | $12.1M | $3.5M | ||
| Q2 24 | $3.1M | $9.9M | ||
| Q1 24 | $1.9M | $12.3M |
自由现金流率AMSCMLAB
| Q4 25 | 3.2% | 27.7% | ||
| Q3 25 | 7.7% | 11.7% | ||
| Q2 25 | 4.6% | 1.5% | ||
| Q1 25 | 7.9% | 19.2% | ||
| Q4 24 | 8.7% | 27.6% | ||
| Q3 24 | 22.3% | 6.0% | ||
| Q2 24 | 7.8% | 16.9% | ||
| Q1 24 | 4.6% | 21.0% |
资本支出强度AMSCMLAB
| Q4 25 | 1.2% | 1.1% | ||
| Q3 25 | 2.1% | 1.8% | ||
| Q2 25 | 1.1% | 1.7% | ||
| Q1 25 | 1.6% | 1.2% | ||
| Q4 24 | 0.9% | 1.3% | ||
| Q3 24 | 1.1% | 3.1% | ||
| Q2 24 | 0.7% | 1.5% | ||
| Q1 24 | 0.7% | 0.9% |
现金转化率AMSCMLAB
| Q4 25 | 0.03× | 5.17× | ||
| Q3 25 | 1.37× | 3.32× | ||
| Q2 25 | 0.61× | 0.40× | ||
| Q1 25 | 5.22× | — | ||
| Q4 24 | 2.38× | — | ||
| Q3 24 | 2.60× | 1.54× | ||
| Q2 24 | — | 3.17× | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AMSC
| Equipment And Systems | $56.0M | 75% |
| Megatran | $14.1M | 19% |
| Comtrafo Industria De Transformadores Eletricos SA | $4.6M | 6% |
MLAB
| Sterilization And Disinfection Control | $24.9M | 38% |
| Biopharmaceutical Development | $14.4M | 22% |
| Other | $14.1M | 22% |
| Clinical Genomics | $11.8M | 18% |
